Key facts
as of Sep 2026- Hemab Therapeutics Holdings’s last known valuation is $386.9M (Oct 2025).
- It has raised $355.1M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($157.0M) in Oct 2025.
- Notable investors include RA Capital Management, Novo Holdings, Sofinnova Partners, The Invus Group, BioInnovation Institute — 12 tracked in total.
- 3 institutional filers report fund marks on Hemab Therapeutics Holdings across 5 filings.
- Status: In IPO Registration.
PA Mark — composite indicative price
LOW confidence~$29per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Hemab Therapeutics Holdings
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Hemab Therapeutics Holdings shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
3 filers · latest Jun 20263 SEC-registered funds reported 5 fair-value marks on Hemab Therapeutics Holdings between May 2026 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsOct 2025Later Stage VC (Series C)$157.0M▮
Feb 2023Early Stage VC (Series B)$137.8M▮
About Hemab Therapeutics Holdings
Developer of prophylactic therapeutics designed for bleeding and thrombosis disorders. The company's therapeutics accumulate, modulate, balance, and at times recruit endogenous clotting factors already present in the blood to the site of injury, enabling patients to form hemostatic plugs or clots to prevent life-threatening complications.
- Industry
- Drug Discovery
- Sector
- Financial Services
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 30
- Website
- hemab.com/
- Ownership
- In IPO Registration